ClinicalTrials.gg
TerminatedNCT03850795Updated Aug 19, 2024

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 3 interventional study of HC-1119 and Enzalutamide in Prostate Cancer Metastatic and Castration-resistant Prostate Cancer, sponsored by Hinova Pharmaceuticals USA, Inc.. Terminated at 58 sites in 14 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Hinova Pharmaceuticals USA, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated by Sponsor for various factors including prolonged duration and enrollment challenges

From the registry’s dates

  • Primary completion was Jun 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Enrollment
38th of 125
104 · median 52
Started
2021
with 3 others
Phase 3
16 of 125
1 open now
Registered
91st of 125
by date

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 38th largest by enrollment, is one of 4 that started in 2021, is one of 16 in phase 3, and was the 91st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This study is a multinational Phase 3, randomized, double-blind, non-inferiority, efficacy and safety study of oral HC-1119 (80 mg/day) versus enzalutamide (160 mg/day) in asymptomatic or mildly symptomatic patients with progressive metastatic castration-resistant prostate cancer (mCRPC).

The following assessment of prostate cancer status will be collected during the course of the trial: soft tissue disease on computed tomography (CT) scan or on magnetic resonance imaging (MRI), bone disease on radionuclide bone scans, FACT-P and EQ-5D, Brief Fatigue Inventory, and PSA.

Throughout the study, safety and tolerability will be assessed by the recording of adverse events, monitoring of vital signs and physical examinations, safety laboratory evaluations, and 12-lead electrocardiograms (ECGs). Blood samples for population pharmacokinetics for HC-1119 and enzalutamide and related metabolites will be collected.

Read the detailed description

This study is a multinational Phase 3, randomized, double-blind, non-inferiority, efficacy and safety study of oral HC-1119 (80 mg/day) versus enzalutamide (160 mg/day) in asymptomatic or mildly symptomatic patients with progressive metastatic castration-resistant prostate cancer (mCRPC). Patients must not have been previously treated with next generation AR-Inhibitors or Androgen-biosynthesis Inhibitors, or prior progression on ketoconazole.

The following assessments of prostate cancer status will be collected during the course of the trial: soft tissue disease on computed tomography (CT) scan or on magnetic resonance imaging (MRI), bone disease on radionuclide bone scans, FACT-P and EQ-5D, Brief Fatigue Inventory, and PSA. Radiographic disease progression is defined by the Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) for soft tissue disease, or the appearance of two or more new bone lesions on bone scan.

Throughout the study, safety and tolerability will be assessed by the recording of adverse events, monitoring of vital signs and physical examinations, safety laboratory evaluations, and 12-lead electrocardiograms (ECGs). Blood samples for population pharmacokinetics for HC-1119 and enzalutamide and related metabolites will be collected pre-dose on Day 1 and prior to dosing on Days 8 (Week 2), 15 (Week 3) and 22 (Week 4), 29 (Week 5), 57 (Week 9), 85 (Week 13) and Day 169 (Week 25). Blood samples for calculating a 24 hour pharmacokinetic profile of HC-1119 and enzalutamide and related metabolites will be collected in a subset of 24 Caucasian (non-Chinese) patients on Day 1 and at steady state in week 9.

Patients will have a safety follow-up visit 30 days after their last dose of study drug or prior to initiation of any new therapy, or an investigational agent, whichever occurs first.

03

Conditions studied

  • Prostate Cancer Metastatic
  • Castration-resistant Prostate Cancer

Browse trials for

Keywords

  • HC-1119
  • enzalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet the following inclusion criteria:

  1. Age 18 or older and willing and able to give .
  2. or cytologically confirmed adenocarcinoma of the prostate without significant and relevant neuroendocrine differentiation or small cell features, per investigator's judgment.
  3. Ongoing ADT with a GnRH analogue, antagonist or bilateral orchiectomy (i.e., surgical or medical castration).
  4. For patients who have not had a bilateral orchiectomy, there must be a plan to maintain effective GnRH analogue or antagonist therapy for the duration of the trial.
  5. Serum testosterone level \< 1.7 nmol/L (50 ng/dL) at the Screening visit.
  6. Patients receiving bisphosphonate or denosumab therapy must have been on stable doses for at least four weeks (from Day 1 visit).
  7. Progressive disease at study entry defined as one or more of the following three criteria that occurred while the patient was on ADT as defined in eligibility criterion #3:

    1. PSA progression defined by a minimum of two rising PSA levels with an interval of ≥ 1 week between each determination. Patients who received an anti-androgen agent must have progression after withdrawal (≥ 4 weeks since last flutamide or ≥ 6 weeks since last bicalutamide or nilutamide). The PSA value at the Screening visit should be ≥ 2 µg/L (2 ng/mL)
    2. Soft tissue disease progression defined by 1.1
    3. Bone disease progression defined by PCWG3 with two or more new lesions on bone scan
  8. disease documented by measurable soft tissue disease by CT/MRI per RECIST 1.1 criteria. Patients are allowed to have any metastatic disease (i.e. bone metastasis) as long as they also have measurable soft tissue lesions per RECIST 1.1..
  9. No prior cytotoxic chemotherapy for prostate cancer.
  10. Asymptomatic or mildly symptomatic from prostate cancer.
  11. performance status of 0-1 per the Investigators' clinical assessment
  12. Estimated of ≥ 6 months
  13. Able to swallow the study drug and comply with study requirements
  14. All sexually active patients are required to use a condom as well as meet 1 of the following:

    1. Patient is non-fertile (orchiectomy) or has a female partner of non- (i.e., , surgically sterilized, hysterectomy)
    2. Patient and his female partner must agree to use an adequate method from the first day of dosing until 3 months after the last dose to prevent pregnancies. Adequate contraceptive method is defined as:

    i. Established use of oral, injected, or implanted hormonal methods of contraception.

    ii. Placement of an intra-uterine device or intra-uterine system. iii. Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.

    iv. Tubal ligation for at least 6 months prior to screening.

  15. Male patient engaged in sexual activity with a pregnant female is required to use a condom from the first day of dosing until 3 months after the last dose of treatment with study drugs.

Exclusion criteria

Exclusion Criteria:

Subjects must NOT meet any of the following exclusion criteria:

  1. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
  2. Known or suspected or active .
  3. Regular daily use of opiate analgesics for pain from prostate cancer within four weeks of enrollment (Day 1 visit).
  4. WBC count \< 3,000/µL, or \< 1,500/µL, or count \< 100,000/µL, or \< 5.6 mmol/L (9 g/dL) at the Screening visit (NOTE: patients may not have received any growth factors or blood transfusions or any therapeutic invention within 14 days of the hematologic laboratory values obtained at the Screening visit).
  5. Total , (ALT) or aspartate aminotransferase (AST) > 2.5 times the at the Screening visit; no therapeutic invention within 14 days before screening.
  6. \< 30 mL/min as calculated using the Cockcroft-Gault equation at the Screening visit. Creatinine Clearance (mL/min) = [[140-Age (years)] * Weight (kg)] / [72 * Serum Creatinine (mg/dL)]
  7. Albumin \< 30 g/L (3.0 g/dL) at the Screening visit, no therapeutic invention within 14 days before screening.
  8. History of another within the previous two years other than curatively treated non-melanomatous skin cancer.
  9. Treatment with flutamide within four weeks of enrollment (Day 1 visit).
  10. Treatment with bicalutamide or nilutamide within six weeks of enrollment (Day 1 visit).
  11. Treatment with 5-α reductase inhibitors (finasteride, dutasteride), estrogens within four weeks of enrollment (Day 1 visit).
  12. Treatment with systemic biologic therapy for prostate cancer (other than approved bone targeted agents) within four weeks of enrollment (Day 1 visit).
  13. Use of herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (e.g., saw palmetto) or systemic greater than the equivalent of 10 mg of prednisone/prednisolone per day within four weeks of enrollment (Day 1 visit).
  14. Prior use, or participation in a clinical trial, of an agent that blocks androgen synthesis (e.g., abiraterone) or blocks the AR (e.g., apalutamide, darolutamide, enzalutamide, proxalutamide).
  15. Participation in a previous clinical trial of HC-1119.
  16. Use of an agent within four weeks of enrollment (Day 1 visit).
  17. Radiation therapy for treatment of the primary tumor within three weeks of enrollment (Day 1 visit).
  18. Radionuclide therapy (Radium 223) for treatment of within four weeks of enrollment (Day 1 visit).
  19. cardiovascular disease or condition
  20. Treatment with strong CYP2C8 inhibitors and inducers, inducers, medications which are known to prolong the (see Appendix C).
  21. History of seizure or any condition that may predispose to seizure.
  22. Conditions that predispose subjects to increased risk for falls or fractures according to the discretion of the Investigator.
  23. Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer disease within last three months).
  24. Major surgery within four weeks prior to enrollment (Day 1 visit).
  25. Have active infection with measured by hepatitis B surface antigen (HBsAg) test, measured by RNA test and measured by antibody test.
  26. Have known active tuberculosis.
  27. Known to HC-1119, enzalutamide, or any of the .
  28. Rare hereditary problems of fructose intolerance due to sorbitol
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    HC-1119

    Oral dose of 80 mg/day

    Drug: HC-1119

  • Active comparator
    enzalutamide

    Oral dose of 160 mg/day

    Drug: Enzalutamide

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    To determine the efficacy of HC-1119 as compared to enzalutamide as assessed by overall response rate (ORR) by RECIST 1.1.

    Time frame: Week 24

Secondary outcomes

  1. PSA decline of ≥50% from baseline

    To determine the efficacy of HC-1119 as compared to enzalutamide as assessed by decline of ≥50% from baseline

    Time frame: Week 24

  2. Radiographic Progression-free Survival (rPFS)

    To determine the efficacy of HC-1119 as compared to enzalutamide as assessed by radiographic progression-free survival (rPFS)

    Time frame: Week 24

  3. Overall Survival (OS)

    To determine the efficacy of HC-1119 as compared to enzalutamide as assessed by overall survival (OS)

    Time frame: Week 24

  4. Safety and Tolerability (based on Common Terminology Criteria for Adverse Events (CTCAE), version 5.0)

    To determine the safety and tolerability of orally administrated HC-1119 as compared to enzalutamide based on Common Terminology Criteria for Adverse Events (CTCAE), version 5.0.

    Time frame: Week 24

07

Study locations

58 sites
  • Urology Center of Colorado, 2777 Mile High Stadium Circle
    Denver, Colorado 80211, United States
  • Urologic Surgeons of Washington
    Washington, District of Columbia 20036, United States
  • First Urology PSC, 101 Hospital Boulevard
    Jeffersonville, Indiana 47130, United States
  • Clinical Research Solutions PC
    Middleburg Heights, Ohio 44130, United States
  • MidLantic Urology
    Bala-Cynwyd, Pennsylvania 19004, United States
  • Keystone Urology Specialists
    Lancaster, Pennsylvania 17604, United States
  • Urology San Antonio Stone Oak, 18915 Meisner Drive
    San Antonio, Texas 78258-4223, United States
  • Providence Regional Cancer System
    Lacey, Washington 98503, United States
  • Icon Cancer Care Gold Coast
    Southport, Queensland 4215, Australia
  • Ashford Cancer Centre Research
    Kurralta Park, South Australia 5037, Australia
  • Affinity Clinical Research
    Nedlands, 6009, Australia
  • Kepler Universitätsklinikum Linz
    Linz, 4020, Austria
  • Fe/Male Health Centre
    Oakville, Ontario L6H 3P1, Canada
  • CIUSSS de l'Estrie-CHUS
    Sherbrooke, Quebec J1H5N4, Canada
  • Aalborg Universitetshospital
    Aalborg, 9000, Denmark
  • Odense Universitetshospital
    Odense C, 5000, Denmark
  • Helsinki University Hospital Comprehensive Cancer Center - PPDS
    Helsinki, 00290, Finland
  • Oulun Yliopistollinen Sairaala
    Oulu, 90220, Finland
  • Seinäjoen Keskussairaala
    Seinäjoki, 60220, Finland
  • Tampereen yliopistollinen sairaala
    Tampere, 33521, Finland
  • Hopital Foch
    Suresnes, Hauts-de-Seine 92151, France
  • Centre Jean Bernard Clinique Victor Hugo
    Le Mans, 72000, France
  • CHRU Lille
    Lille Cedex, 59037, France
  • Centre Léon Berard
    Lyon, 69008, France
  • Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
  • Hopital d'Instruction des Armées de Begin
    Saint-Mandé, 94160, France
  • Urologische Studienpraxis
    Nürtingen, Baden-Württemberg 72622, Germany
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
  • Universitätsklinikum Tübingen
    Tübingen, 72076, Germany
  • UroGynZentrum Wall
    Wuppertal, 42103, Germany
  • Azienda Ospedaliera S Maria Di Terni
    Terni, Umbria, Italy
  • Azienda Ospedaliera Universitaria Integrata Di Verona
    Verona, 37126, Italy
  • Antonius Ziekenhuis
    Sneek, Friesland 8601 ZK, Netherlands
  • Canisius Wilhelmina Ziekenhuis
    Nijmegen, Gelderland 6532 SZ, Netherlands
  • Catharina Hospital
    Eindhoven, Noord-Brabant 5623 EJ, Netherlands
  • Hagaziekenhuis
    Den Haag, Zuid-Holland 2545 AA, Netherlands
  • NZOZ Centrum Urologiczne Sp zoo
    Mysłowice, Slaskie 41-400, Poland
  • Clinical Research Center Spolka z Ograniczona
    Poznań, Wielkopolskie 60-848, Poland
  • Onko-Centrum Sp. z o.o.
    Lublin, 20-250, Poland
  • Urologica Praktyka Lekarska Adam Marcheluk
    Siedlce, 08-110, Poland
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy
    Warszawa, 02-781, Poland
  • Altay Regional Oncology Center
    Barnaul, 656045, Russian Federation
  • Ivanovo Regional Oncology Dispensary
    Ivanovo, 153040, Russian Federation
  • Federal State Institution Medical Radiology Research Center
    Obninsk, 249036, Russian Federation
  • Clinical Oncology Dispensary
    Omsk, 644013, Russian Federation
  • First St. Petersburg State Medical University n.a. I.P Pavlov
    Saint Petersburg, 197022, Russian Federation
  • GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology)
    Saint Petersburg, 197758, Russian Federation
  • Hospital Orkli LLC
    Saint Petersburg, 199178, Russian Federation
  • C.H. Regional Reina Sofia - PPDS
    Córdoba, 14004, Spain
  • Hospital Lucus Augusti
    Lugo, 27003, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Regional Universitario de Malaga - Hospital Civil
    Málaga, 29009, Spain
  • Hospital Universitario Virgen del Rocio - PPDS
    Sevilla, 41013, Spain
  • Fundacion Instituto Valenciano de Oncologia
    Valencia, 46009, Spain
  • Diana Princess of Wales Hospital
    Grimsby, South Humberside DN33 2BA, United Kingdom
  • Belfast City Hospital
    Belfast, BT9 7AB, United Kingdom
  • Royal Marsden Hospital - London
    London, SW3 6JJ, United Kingdom
  • Mount Vernon Hospital
    Northwood, HA6 2RN, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jun 2024, 39 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Feb 22, 2019
StartActual
Mar 15, 2021
Primary completionActual
Jun 28, 2024
CompletionActual
Jun 28, 2024
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03850795
Lead sponsor
Hinova Pharmaceuticals USA, Inc.
Responsible party
Sponsor
First posted
Feb 22, 2019
Start date
Mar 15, 2021
Primary completion
Jun 28, 2024
Completion
Jun 28, 2024
Last update
Aug 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion